Business

New Alzheimer’s treatment could decrease number of harmful proteins by up to 59% 

Research shows that the new Alzheimer’s treatment could decrease number of harmful proteins by up to 59% in humans

A new Alzheimer’s treatment may be able to remove proteins associated with cognitive decline related to the age-related brain disease, a new study finds.

Researchers from the NYU Grossman School of Medicine found that elderly monkeys given a new drug saw a decrease of amyloid beta plaques and tau tangles by up to 59 percent.

The treatment ‘swallows’ the amyloid beta proteins that clog nerve cells and cause cognitive decline.

It comes as Alzheimer’s treatment is at the forefront of the medical world, with Biogen Inc’s aducanumab – the first medication in nearly two decades – was given approval by the U.S. Food and Drug Administration (FDA).

A study conducted at NYU Langone Health found that a new Alzheimer’s treatment has been effected in preventing cognitive decline in squirrel monkeys

‘Our findings illustrate that this therapy is an effective way of manipulating the immune system to slow neurodegeneration,’ said Akash Patel, an assistant research scientist in the Center for Cognitive Neurology at NYU Langone Health, in a statement.

HOW TO DETECT ALZHEIMER’S DISEASE

Alzheimer’s disease is a progressive brain disorder that slowly destroys memory, thinking skills and the ability to perform simple tasks.

It is the cause of 60% to 70% of cases of dementia.

The majority of people with Alzheimer’s are age 65 and older

More than six million Americans have Alzheimer’s.

 It is unknown what causes Alzheimer’s. Those who have the APOE gene are more likely to develop late-onset Alzheimer’s.

Signs and symptoms:

  • Difficulty remembering newly learned information
  • Disorientation
  • Mood and behavioral changes
  • Suspicion about family, friends and professional caregivers
  • More serious memory loss
  • Difficulty with speaking, swallowing and walking

Stages of Alzheimer’s:

  • Mild Alzheimer’s (early-stage) – A person may be able to function independently but is having memory lapses
  • Moderate Alzheimer’s (middle-stage) – Typically the longest stage, the person may confuse words, get frustrated or angry, or have sudden behavioral changes
  • Severe Alzheimer’s disease (late-stage) – In the final stage, individuals lose the ability to respond to their environment, carry on a conversation and, eventually, control movement

Researchers used 15 female squirrel monkeys for the study because squirrel monkeys all develop brain conditions comparable to Alzheimer’s in humans.

Eight were treated with a single dose of the CpG oligodeoxynucleotides (CpG ODN) for two years, while seven were treated with a placebo.

CpG ODN are short synthetic single-stranded DNA molecules the boost the immune responses of cells.

Researchers compared brain scans and blood samples of the two groups, while also giving the monkeys cognitive tests like puzzles to solve.

The monkeys in the research group showed lower levels of the degenerative proteins and also outperformed the control group on cognitive tests.

‘The similarities in aging between the animals studied and our own species give us hope that this therapy will work in human patients as well,’ said Dr Henrieta Scholtzona, co-senior author of the study and associate professor of neurology at NYU Langone Health, in a statement.

Sholtzona does note that they only used elderly monkeys for the test, and more research will need to be done to find whether the treatment can prevent Alzheimer’s from a younger age.

Researchers believe their drug is more effective than past drugs that have been trialed, as they are not targeting the immune system but instead the brain directly.

Alzheimer’s is the sixth leading cause of death in the United States.

More than 100,000 Americans die every year from the condition and nearly six million Americans are believed to have it.

Last week, the first new Alzheimer’s drug to be available for the public in America since 2003 was given FDA approval.

Aducanumab, which is developed by Biogen and will be sold under the name Aduhelm, received controversial approval after a rocky trial period.

The drug went through two clinical trials, both were ended early as they were believed to have failed.

Data from the second trial was later used to show the drug could potentially stop cognitive decline by 22 percent, though many in the scientific community disagree with the findings.

Daily Mail Online

Source

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button